Case Report: Alpelisib-Induced Drug Reaction With Eosinophilia and Systemic Symptoms: A Rare Manifestation of a Common Side Effect

Alpelisib is a PIK3a inhibitor approved for the treatment of metastatic ER+ breast cancer in combination with fulvestrant. Although rash is a common side effect of this medication, we present the first case of drug reaction with eosinophilia and systemic symptoms (DRESS) upon initial exposure to alp...

Descripción completa

Detalles Bibliográficos
Autores principales: Majeed, Umair, Puiu, Tudor, Sluzevich, Jason, Reynolds, Gina, Acampora, Marites, Moreno-Aspitia, Alvaro, Bodiford, Katherine J., Advani, Pooja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421674/
https://www.ncbi.nlm.nih.gov/pubmed/34504802
http://dx.doi.org/10.3389/fonc.2021.726785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421674/
https://www.ncbi.nlm.nih.gov/pubmed/34504802
http://dx.doi.org/10.3389/fonc.2021.726785

Ejemplares similares